-
Je něco špatně v tomto záznamu ?
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
N. Lizak, A. Lugaresi, R. Alroughani, J. Lechner-Scott, M. Slee, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, P. Grammond, R. Hupperts, F. Grand'Maison, P. Sola, E. Pucci, R. Bergamaschi, C. Oreja-Guevara,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, pozorovací studie
NLK
ProQuest Central
od 1944-07-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 1944-07-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1944-07-01 do Před 6 měsíci
Psychology Database (ProQuest)
od 1944-07-01 do Před 6 měsíci
PubMed
27683916
DOI
10.1136/jnnp-2016-313976
Knihovny.cz E-zdroje
- MeSH
- imunomodulace imunologie MeSH
- kohortové studie MeSH
- lidé MeSH
- postižení * MeSH
- posuzování pracovní neschopnosti MeSH
- progrese nemoci * MeSH
- relabující-remitující roztroušená skleróza farmakoterapie imunologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. METHODS: The epochs between Expanded Disability Status Scale (EDSS) steps 3-6, 4-6 and 6-6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/6) were identified in MSBase, a global observational MS cohort study. We used multivariable survival models to examine the impact of disease-modifying therapy, clinical and demographic factors on progression to the outcome EDSS step (6/6.5). Sensitivity analyses with varying outcome definitions and inclusion criteria were conducted. RESULTS: For the EDSS 3-6, 4-6 and 6-6.5 epochs, 1560, 1504 and 1231 patients were identified, respectively. Disability trajectories showed large coefficients of variance prebaseline (0.92-1.11) and postbaseline (2.15-2.50), with no significant correlations. The probability of reaching the outcome step was not associated with prebaseline variables, but was increased by higher relapse rates during each epoch (HRs 1.58-3.07; p<0.001). A greater proportion of each epoch treated with higher efficacy therapies was associated with lower risk of reaching the outcome disability step (HRs 0.72-0.91 per 25%; p≤0.02). 3 sensitivity analyses confirmed these results. CONCLUSIONS: Disease progression during moderately advanced and advanced MS is highly variable and amnesic to prior disease activity. Lower relapse rates and greater time on higher efficacy immunomodulatory therapy after reaching EDSS steps 3, 4 and 6 are associated with a decreased risk of accumulating further disability. Highly effective immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced relapse-onset MS.
AORN San Giuseppe Moscati Avellino Italy
Assaf Harofeh Medical Center Beer Yaakov Israel
C Mondino National Neurological Institute Pavia Italy
Cliniques Universitaires Saint Luc Brussels Belgium
Department of Basic Medical Sciences Neuroscience and Sense Organs University of Bari Bari Italy
Department of Neurology Amiri Hospital Kuwait City Kuwait
Department of Neurology Donostia University Hospital San Sebastian Spain
Flinders University and Medical Centre Adelaide Australia
Groen Hart Ziekenhuis Gouda The Netherlands
Hôpital Notre Dame Montreal Canada
Hospital Fernàndez Buenos Aires Argentina
Hospital Germans Trias i Pujol Badalona Spain
Hospital Italiano Buenos Aires Argentina
Hospital Universitario Virgen Macarena Sevilla Spain
Hotel Dieu de Levis Quebec Canada
Hunter Medical Research Institute University of Newcastle Newcastle Australia
Jahn Ferenc Teaching Hospital Budapest Hungary
Karadeniz Technical University Trabzon Turkey
Liverpool Hospital Sydney Australia
Neuro Rive Sud Hôpital Charles LeMoyne Quebec Canada
Neurology Unit ASUR Marche AV 3 Macerata Italy
Neurology Unit Department of Neuroscience Nuovo Ospedale Civile Sant'Agostino Estense Modena Italy
Ospedali Riuniti di Salerno Salerno Italy
Section of Neurosciences Department NEUROFARBA University of Florence Florence Italy
University Hospital San Carlos IdISSC Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023666
- 003
- CZ-PrNML
- 005
- 20170906112304.0
- 007
- ta
- 008
- 170720s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/jnnp-2016-313976 $2 doi
- 035 __
- $a (PubMed)27683916
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lizak, Nathaniel $u Department of Medicine, University of Melbourne, Melbourne, Australia. Monash School of Medicine, Monash University, Melbourne, Australia.
- 245 10
- $a Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis / $c N. Lizak, A. Lugaresi, R. Alroughani, J. Lechner-Scott, M. Slee, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, P. Grammond, R. Hupperts, F. Grand'Maison, P. Sola, E. Pucci, R. Bergamaschi, C. Oreja-Guevara, V. Van Pesch, C. Ramo, D. Spitaleri, G. Iuliano, C. Boz, F. Granella, J. Olascoaga, F. Verheul, C. Rozsa, E. Cristiano, S. Flechter, S. Hodgkinson, MP. Amato, N. Deri, V. Jokubaitis, T. Spelman, H. Butzkueven, T. Kalincik, . ,
- 520 9_
- $a OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. METHODS: The epochs between Expanded Disability Status Scale (EDSS) steps 3-6, 4-6 and 6-6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/6) were identified in MSBase, a global observational MS cohort study. We used multivariable survival models to examine the impact of disease-modifying therapy, clinical and demographic factors on progression to the outcome EDSS step (6/6.5). Sensitivity analyses with varying outcome definitions and inclusion criteria were conducted. RESULTS: For the EDSS 3-6, 4-6 and 6-6.5 epochs, 1560, 1504 and 1231 patients were identified, respectively. Disability trajectories showed large coefficients of variance prebaseline (0.92-1.11) and postbaseline (2.15-2.50), with no significant correlations. The probability of reaching the outcome step was not associated with prebaseline variables, but was increased by higher relapse rates during each epoch (HRs 1.58-3.07; p<0.001). A greater proportion of each epoch treated with higher efficacy therapies was associated with lower risk of reaching the outcome disability step (HRs 0.72-0.91 per 25%; p≤0.02). 3 sensitivity analyses confirmed these results. CONCLUSIONS: Disease progression during moderately advanced and advanced MS is highly variable and amnesic to prior disease activity. Lower relapse rates and greater time on higher efficacy immunomodulatory therapy after reaching EDSS steps 3, 4 and 6 are associated with a decreased risk of accumulating further disability. Highly effective immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced relapse-onset MS.
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a posuzování pracovní neschopnosti $7 D004185
- 650 12
- $a postižení $7 D006233
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunomodulace $x imunologie $7 D056747
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x imunologie $7 D020529
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Lugaresi, Alessandra $u Department of Biomedical and Neuromotor Sciences, University of Bologna and IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
- 700 1_
- $a Alroughani, Raed $u Department of Neurology, Amiri Hospital, Kuwait City, Kuwait. $7 gn_A_00004804
- 700 1_
- $a Lechner-Scott, Jeannette $u Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia.
- 700 1_
- $a Slee, Mark $u Flinders University and Medical Centre, Adelaide, Australia.
- 700 1_
- $a Havrdova, Eva $u 1st Faculty of Medicine, Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Praha, Czech Republic.
- 700 1_
- $a Horakova, Dana $u 1st Faculty of Medicine, Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Praha, Czech Republic.
- 700 1_
- $a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.
- 700 1_
- $a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Sevilla, Spain.
- 700 1_
- $a Duquette, Pierre $u Hôpital Notre Dame, Montreal, Canada.
- 700 1_
- $a Girard, Marc $u Hôpital Notre Dame, Montreal, Canada.
- 700 1_
- $a Prat, Alexandre $u Hôpital Notre Dame, Montreal, Canada.
- 700 1_
- $a Grammond, Pierre $u Hotel-Dieu de Levis, Quebec, Canada.
- 700 1_
- $a Hupperts, Raymond $u Zuyderland Ziekenhuis, Sittard, The Netherlands.
- 700 1_
- $a Grand'Maison, Francois $u Neuro Rive-Sud, Hôpital Charles LeMoyne, Quebec, Canada.
- 700 1_
- $a Sola, Patrizia $u Neurology Unit, Department of Neuroscience, Nuovo Ospedale Civile Sant'Agostino/Estense, Modena, Italy.
- 700 1_
- $a Pucci, Eugenio $u Neurology Unit, ASUR Marche-AV 3, Macerata, Italy.
- 700 1_
- $a Bergamaschi, Roberto $u C. Mondino National Neurological Institute, Pavia, Italy.
- 700 1_
- $a Oreja-Guevara, Celia $u University Hospital San Carlos, IdISSC, Madrid, Spain.
- 700 1_
- $a Van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- 700 1_
- $a Ramo, Cristina $u Hospital Germans Trias i Pujol, Badalona, Spain.
- 700 1_
- $a Spitaleri, Daniele $u AORN San Giuseppe Moscati, Avellino, Italy.
- 700 1_
- $a Iuliano, Gerardo $u Ospedali Riuniti di Salerno, Salerno, Italy.
- 700 1_
- $a Boz, Cavit $u Karadeniz Technical University, Trabzon, Turkey.
- 700 1_
- $a Granella, Franco $u University of Parma, Parma, Italy.
- 700 1_
- $a Olascoaga, Javier $u Department of Neurology, Donostia University Hospital, San Sebastian, Spain.
- 700 1_
- $a Verheul, Freek $u Groen Hart Ziekenhuis, Gouda, The Netherlands.
- 700 1_
- $a Rozsa, Csilla $u Jahn Ferenc Teaching Hospital, Budapest, Hungary.
- 700 1_
- $a Cristiano, Edgardo $u Hospital Italiano, Buenos Aires, Argentina.
- 700 1_
- $a Flechter, Shlomo $u Assaf Harofeh Medical Center, Beer-Yaakov, Israel.
- 700 1_
- $a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, Australia.
- 700 1_
- $a Amato, Maria Pia $u Section of Neurosciences, Department NEUROFARBA, University of Florence, Florence, Italy. $7 gn_A_00005308
- 700 1_
- $a Deri, Norma $u Hospital Fernàndez, Buenos Aires, Argentina.
- 700 1_
- $a Jokubaitis, Vilija $u Department of Medicine, University of Melbourne, Melbourne, Australia. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
- 700 1_
- $a Spelman, Tim $u Department of Medicine, University of Melbourne, Melbourne, Australia. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
- 700 1_
- $a Butzkueven, Helmut $u Department of Medicine, University of Melbourne, Melbourne, Australia. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. Box Hill Hospital, Monash University, Melbourne, Australia.
- 700 1_
- $a Kalincik, Tomas
- 700 1_
- $a ,
- 773 0_
- $w MED00010064 $t Journal of neurology, neurosurgery, and psychiatry $x 1468-330X $g Roč. 88, č. 3 (2017), s. 196-203
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27683916 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170906112902 $b ABA008
- 999 __
- $a ok $b bmc $g 1239347 $s 984579
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 88 $c 3 $d 196-203 $e 20160928 $i 1468-330X $m Journal of neurology, neurosurgery and psychiatry $n J Neurol Neurosurg Psychiatry $x MED00010064
- LZP __
- $a Pubmed-20170720
